Atezolizumab with cabozantinib for previously treated metastatic castration-resistant prostate cancer


featured image

Atezolizumab in combination with cabozantinib is in clinical development for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in male patients previously treated with one novel hormonal therapy (NHT).

Indications: Prostate cancer
Therapeutic Areas: Male Reproductive Cancer
Year: 2022

Atezolizumab in combination with cabozantinib is in clinical development for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in male patients previously treated with one novel hormonal therapy (NHT). Prostate cancer is cancer of the prostate gland, which is part of the male reproductive system. When prostate cancer spreads to other parts of the body, it is called metastatic. Castration-resistant refers to when prostate cancer does not respond to initial treatments, which include surgery and/or a standard hormone treatment called androgen-deprivation therapy that lowers testosterone levels in the body to slow cancer growth. There is a significant unmet need for effective therapies in patients with mCRPC who have received prior NHT.